Does Zantac Cause Cancer?

The FDA has found N-nitrosodimethylamine (NDMA), a probable human carcinogen, levels in some ranitidine products increase with time and temperature, posing a risk to consumers. Therefore, the FDA has requested the withdrawal of all ranitidine products from the U.S. market.

Complete the form below to find out if you qualify for compensation.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

NDMA Is a Probable Human Carcinogen

(a substance that could cause cancer)

In April 2020, the FDA issued an immediate market withdrawal request for all prescription and over-the-counter versions of Zantac and generic ranitidine products because the drugs could contain high levels of NDMA, a chemical found to be a probable human carcinogen. Studies showed that NDMA levels in these products increase over time or when stored in higher temperatures.

Research is still being conducted to determine if NDMA in Zantac (ranitidine) is linked to bladder cancer, kidney cancer or kidney removal, breast cancer, liver cancer, stomach cancer, and prostate cancer.

ndma
infographic

Cancer Types Linked to Zantac (Ranitidine)

If you or a family member developed one of these cancers after using Zantac or ranitidine products for more than 3 months, you may be eligible to file a lawsuit against the drug manufacturers:

  • Gastric/stomach cancer
  • Esophageal cancer
  • Liver cancer
  • Bladder cancer
  • Rectal cancer (not merely colorectal)

Zantac (Ranitidine) Side Effects

Individuals who have taken Zantac or other ranitidine drugs may experience these side effects, according to the National Institute of Health:

  • Chest pain not associated with heartburn
  • Constipation
  • Dark urine
  • Diarrhea
  • Headache
  • Nausea
  • Shortness of breath
  • Stomach pain
  • Vomiting